CONFERENCE UPDATE: ASCO 2022

Long-term outcomes from JAVELIN Bladder 100: Avelumab as 1L maintenance + BSC vs. BSC alone for patients with aUC whose disease had not progressed with 1L chemotherapy

UROLOGY ONCOLOGY
27 Jul 2022

Glossary: 1L: First-line; AEs: Adverse events; aUC: Advanced urothelial carcinoma; BSC: Best support care; CI: Confidence interval; CR: Complete response; HR: Hazard ratio; mUC: Metastatics urothelial carcinoma; NE: Not estmable; OS: Overall survival; PD-L1: Programmed death-ligand 1; PFS: Progression-free survival; PR: Partial response; Q2W: Every 2 weeks; SD: Stable disease; TEAEs: Treatment-emergent adverse events

Get access to our exclusive articles.
Related Articles

Consistent OS benefits with avelumab 1L maintenance in aUC irrespective of 1L chemotherapy

In the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2023, Sridhar SS, et al. reported the post hoc analyses of the long-term outcomes of the phase 3 JAVELIN Bladder 100 trial, showing significantly longer overall survival (OS) with avelumab first-line (1L) maintenance
ONCOLOGY UROLOGY
06 Apr 2023